Sunmax Biotechnology Co., Ltd. (TPEX:4728)
Taiwan
· Delayed Price · Currency is TWD 387.50
-1.00 (-0.26%)
Apr 29, 2026, 1:24 PM CST
Sunmax Biotechnology Revenue
In the year 2025, Sunmax Biotechnology had annual revenue of 2.03B TWD with 11.45% growth. Sunmax Biotechnology had revenue of 508.27M in the quarter ending December 31, 2025, with 6.07% growth.
Revenue
2.03B
Revenue Growth
+11.45%
P/S Ratio
10.44
Revenue / Employee
n/a
Employees
n/a
Market Cap
21.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.03B | 208.15M | 11.45% |
| Dec 31, 2024 | 1.82B | 129.03M | 7.64% |
| Dec 31, 2023 | 1.69B | 288.91M | 20.64% |
| Dec 31, 2022 | 1.40B | 364.42M | 35.19% |
| Dec 31, 2021 | 1.04B | 179.81M | 21.01% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lumosa Therapeutics | 35.83M |
| Oneness Biotech | 129.12M |
| AP Biosciences | 32.25M |
| Medigen Vaccine Biologics | 613.17M |
| Polaris Group | 40.60M |
| EirGenix | 1.01B |
| TaiMed Biologics | 611.35M |
| Locus Cell | 12.74M |